These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 24436439

  • 1. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Kim SM, Woo JS, Jeong CH, Ryu CH, Jang JD, Jeun SS.
    Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
    [Abstract] [Full Text] [Related]

  • 2. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886.
    Kim SM, Woo JS, Jeong CH, Ryu CH, Lim JY, Jeun SS.
    Cancer Res; 2012 Sep 15; 72(18):4807-17. PubMed ID: 22962275
    [Abstract] [Full Text] [Related]

  • 3. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
    Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K.
    Mol Cancer Ther; 2008 Nov 15; 7(11):3575-85. PubMed ID: 19001440
    [Abstract] [Full Text] [Related]

  • 4. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM, Oh JH, Park SA, Ryu CH, Lim JY, Kim DS, Chang JW, Oh W, Jeun SS.
    Stem Cells; 2010 Dec 15; 28(12):2217-28. PubMed ID: 20945331
    [Abstract] [Full Text] [Related]

  • 5. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
    Choi SA, Lee C, Kwak PA, Park CK, Wang KC, Phi JH, Lee JY, Chong S, Kim SK.
    Cancer Lett; 2019 Feb 01; 442():161-169. PubMed ID: 30367915
    [Abstract] [Full Text] [Related]

  • 6. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L, Zhu J.
    Neurosurgery; 2009 Sep 10; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
    Dong J, Zhou G, Tang D, Chen Y, Cui B, Dai X, Zhang J, Lan Q, Huang Q.
    J Cancer Res Clin Oncol; 2012 Dec 10; 138(12):2079-84. PubMed ID: 22825126
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
    Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, Oh W, Park SH, Sung YC, Jeun SS.
    Cancer Res; 2008 Dec 01; 68(23):9614-23. PubMed ID: 19047138
    [Abstract] [Full Text] [Related]

  • 15. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y, Dong L, Bao S, Wang M, Yun Y, Zhu R.
    Biomed Pharmacother; 2016 Dec 01; 84():462-469. PubMed ID: 27685789
    [Abstract] [Full Text] [Related]

  • 16. Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
    Li XQ, Ouyang ZG, Zhang SH, Liu H, Shang Y, Li Y, Zhen YS.
    J Neurooncol; 2014 Aug 01; 119(1):91-100. PubMed ID: 24842385
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
    Liu XY, Zhang L, Wu J, Zhou L, Ren YJ, Yang WQ, Ming ZJ, Chen B, Wang J, Zhang Y, Yang JM.
    PLoS One; 2013 Aug 01; 8(11):e81345. PubMed ID: 24303044
    [Abstract] [Full Text] [Related]

  • 18. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
    Gong A, Ge N, Yao W, Lu L, Liang H.
    Cancer Chemother Pharmacol; 2014 Sep 01; 74(3):531-8. PubMed ID: 25047724
    [Abstract] [Full Text] [Related]

  • 19. Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
    Uzzaman M, Keller G, Germano IM.
    J Neurosurg; 2007 Apr 01; 106(4):646-51. PubMed ID: 17432717
    [Abstract] [Full Text] [Related]

  • 20. Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial glioma.
    Park SA, Han HR, Ahn S, Ryu CH, Jeun SS.
    Oncol Rep; 2021 Mar 01; 45(3):869-878. PubMed ID: 33469674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.